Pharmaceuticals company Gland Pharma announced Q1FY24 results: Revenue from operations of Rs 12,087 million in Q1FY24 compared to Rs 8,569 million in Q1FY23, up 41% YoY Gross Profit of Rs 7,558 million in Q1FY24 comapred to Rs 4,828 million in Q1FY23, up 57% YoY EBITDA of Rs 2,982 million in Q1FY24 comapred to Rs 2,699 million in Q1FY23, up 10% YoY EBITDA Margin of 25% in Q1FY24 comapred to 31% in Q1FY23 PBT of Rs 2,613 million in Q1FY24 comapred to Rs 3,085 million in Q1FY23, down 15% YoY PAT of Rs 1,941 million in Q1FY24 compared to Rs 2,292 million in Q1FY23, down 15% YoY Total Capex incurred during Q1FY24 was Rs 687 million Commenting on the results, Srinivas Sadu, MD & CEO, Gland Pharma said, “I am pleased to share that the efforts made for business recovery, after a challenging previous year, are yielding fruitful results. I would like to congratulate our team for their relentless efforts in launching 33 product SKUs during this quarter. The operating revenue for the quarter stood at Rs 12,087 million, a YoY growth of 41% with an EBITDA of Rs 2,982 million. The outcomes of the recently conducted US FDA inspections at three of our sterile facilities demonstrate our commitment to being a quality-focused and regulatory-compliant company. Maintaining an unwavering focus on quality and regulatory compliance establishes trust with our partners and will keep us in good stead in further strengthening our customer base.” Result PDF